Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND AIMS: Ex vivo expansion of natural killer (NK) cells is a strategy to produce large numbers of these effector cells for immunotherapy. However, the transfer of bench-top expansion protocols to clinically applicable methods is challenging for NK cell-based therapy because of regulatory aspects and scale-up issues. Therefore, we developed an automated, large-scale NK cell expansion process. METHODS: Enriched NK cells were expanded with interleukin-2 and irradiated clinical-grade Epstein-Barr virus-transformed lymphoblastoid feeder cells with the use of an automated system in comparison to manual expansion, and the cells were investigated for their functionality, phenotype and gene expression. RESULTS: Automated expansion resulted in a mean 850-fold expansion of NK cells by day 14, yielding 1.3 (± 0.9) × 10(9) activated NK cells. Automatically and manually produced NK cells were comparable in target cell lysis, degranulation and production of interferon-γ and tumor necrosis factor-α and had similar high levels of antibody-dependent cellular cytotoxicity against rituximab-treated leukemic cells. NK cells after automated or manual expansion showed similar gene expression and marker profiles. However, expanded NK cells differed significantly from primary NK cells including upregulation of the functional relevant molecules TRAIL and FasL and NK cell-activating receptors NKp30, NKG2D and DNAM-1. Neither automatically nor manually expanded NK cells showed reduced telomere length indicative of a conserved proliferative potential. CONCLUSIONS: We established an automated method to expand high numbers of clinical-grade NK cells with properties similar to their manually produced counterparts. This automated process represents a highly efficient tool to standardize NK cell processing for therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Cited by
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Vari, F., Arpon, D., Keane, C., Hertzberg, M. S., Talaulikar, D., Jain, S., Cui, Q., Han, E., Tobin, J., Bird, R., et al. (2018) · Blood · doi:10.1182/blood-2017-07-796342 · Cited by 313
Mock, U., Nickolay, L., Philip, B., Cheung, G. W.-K., Zhan, H., Johnston, I. C. D., Kaiser, A. D., Peggs, K., Pule, M., Thrasher, A. J., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.009 · Cited by 237
“To simplify the protocol and minimize potential risks during the process, the CliniMACS Prodigy [8] has been adapted to automate clinical-scale manufacturing of cell products [9–11].”
MethodEngineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
Schmidt, P., Raftery, M. J., & Pecher, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611163 · Cited by 106
“membrane-bound cytokines (IL-15 and IL-21) and are irradiated before being used (11).”
Background
Metadata
- Authors
- Granzin, M., Soltenborn, S., Müller, S., Kollet, J., Berg, M., Cerwenka, A., Childs, R. W., & Huppert, V.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 17
- Issue
- 5
- Pages
- 621-632
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2170792469
- Cited by
- 98
- References
- 3
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. https://app.cochat.ai/papers/10.1016/j.jcyt.2015.03.611
- The paper
- Granzin, M., Soltenborn, S., Müller, S., Kollet, J., Berg, M., Cerwenka, A., Childs, R. W., & Huppert, V. (2015). Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. https://doi.org/10.1016/j.jcyt.2015.03.611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.